FIRST SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPENDENCE REFRACTORY TO ERYTHROPOIETIN THERAPY
Introduction: Luspatercept is a recent breakthrough in the therapy of anemia in low-risk MDS. Methods: From January 2021 to October 2023, 44 patients (median age 77, M/F 25/19, WHO 2016 classification: MDS-RS-MLD 28, MDS-MLD -4, RARS-T 8, CMML- 0 2, 5q- + RS 2, IPSS-R: very low 2, low 33, Intermedia...
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Elsevier
2024-01-01
|
| Saila: | Leukemia Research Reports |
| Sarrera elektronikoa: | http://www.sciencedirect.com/science/article/pii/S2213048924000347 |